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Two GTP-binding proteins (G-proteins) of 22 kDa were purified to near homogeneity from a sodium cholate extract 
of human platelet membranes by successive chromatographies on DEAE-Sephacel, Ultrogel AcA-44, phenyl-Sepharose 
CL-4B, Mono Q HR5/5 and hydroxyapatite columns. They bound maximally 0.89 mol of P”S]guanosine 5’-(3-O-thio)tri- 
phosphate per mol of both purified proteins, and this binding was inhibited by GTP and GDP but not by ATP and 
AppNHp. Their molecular masses were somewhat lower than that of ras p21 and they were not recognized by an anti-v- 
Ki-ras p21 antibody. These results indicate that human platelet membranes contain at least two low-molecular-mass G- 
proteins distinct from ras ~21, in addition to .the heterotrimeric G-proteins, the a-subunits of which possess molecular 
mass values of about 40 kDa. 
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1. INTRODUCTION 
It is well known that structurally and functional- 
ly homologous membrane-bound GTP-binding 
proteins (G-proteins) occur in a variety of mam- 
malian cells. Among them, the stimulatory (Gs) 
and inhibitory (Gil) G-proteins for hormone- 
sensitive adenylate cyclase [l] and transducin (Gt) 
involved in retinal light reception [2] are best 
characterized. In addition, Go and Giz (a,&) 
have been purified from brain, though their func- 
tions remain unknown [3-71. All these G-proteins 
have been shown to possess a heterotrimeric struc- 
ture (a;oY) [l-7]. Recent molecular cloning of 
genes and cDNAs encoding their a-subunits has 
revealed that in addition to the heterogeneity of the 
a-subunit according to which these G-proteins are 
classified into major classes (Gs, Gi and Gt), there 
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are multiple forms of the subunit within each class 
[8-151. 
Accumulating evidence indicates the occurrence 
of another group of G-proteins having molecular 
masses between 20 and 30 kDa, besides the above- 
mentioned heterotrimeric G-proteins. Proteins en- 
coded by three ras genes, Ki-ras, Ha-ras and N-ras, 
appear to belong to this group, because these pro- 
teins exhibit GTP-binding and GTPase activities 
[ 16-181. G-proteins belonging to this group have 
so far been purified and characterized from such 
sources as rabbit liver [19], bovine brain [20,21] 
and human placenta [22]. SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) of human platelet 
membranes and subsequent blotting of the 
separated polypeptide bands to nitrocellulose 
sheets have shown the presence of several low- 
molecular-mass G-proteins capable of binding 
[~u-~‘P]GTP (23-27 kDa [23]; 21, 27, 29 and 
29.5 kDa [24]). However, none of the G-proteins 
from platelets have been purified. We report here 
the purification and characterization of two G- 
proteins both of which have a molecular mass of 
about 22 kDa from human platelet membranes. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Guanosine 5 ’ -(3-0-thio)triphosphate (GTPyS) was pur- 
chased from Boehringer, Mannheim. [35S]GTPyS and 
[adeny/ate-3zP]nicotinamide adenine dinucleotide ([“PINAD) 
were from Du Pont-New England Nuclear. Islet-activating pro- 
tein (IAP) was from Kaken Pharmaceutical Co. v-ras p21 syn- 
thesized in Escherichia co/i was a generous gift from Dr H. 
Nakano of Kyowa Hakko Kogyo Co., Tokyo. A monoclonal 
antibody against v-Ki-ras p21 was kindly supplied by Dr H. 
Shiku of Nagasaki University. 
2.2. Assays of activities and immunoblot procedures 
Binding of [“S]GTPyS to GTP-binding proteins and IAP- 
mediated ADP-ribosylation were assayed according to the 
method described earlier [6]. Electrophoresis of polypeptides 
through SDS-polyacrylamide gels and the treatment of the sam- 
ple with N-ethylmaleimide are described in [3]. Immunoblot 
analysis was performed essentially as described in [7]. 
2.3. Preparation of human platelet membrane extracts 
All procedures were carried out at 4°C. Outdated human 
platelet concentrate was centrifuged at 200 x g for 5 min to 
remove contaminating erythrocytes. The supernatant was 
separated and centrifuged at 2000 x g for 20 min. The pelleted 
platelets were then washed twice with 20 mM Tris-malate buffer 
(pH 7.0)/S mM EGTA/l mM phenylmethylsulfonyl fluoride 
(PMSF) (buffer A) and were disrupted by sonication for a total 
of 10 min with 15-s burst of probe sonicator (Branson Sonifier 
B-12). The membrane fraction was obtained by centrifugation 
at 105000 x g for 1 h, washed once with buffer A, and ex- 
tracted with 200 ml of 20 mM Tris-HCl (pH 8.0)/l mM 
EDTA/l mM dithiothreitol (DTT)/O.S mM PMSF (TEDP) 
containing 2% sodium cholate. After incubation for 2 h with 
stirring, the cholate extract was obtained by centrifugation at 
105000 x g for 1 h for purification of G-proteins. 
3. RESULTS AND DISCUSSION 
The sodium cholate extract of human platelet 
membranes (1165 mg protein) was applied to a 
DEAE-Sephacel (Pharmacia) column (4.4 x 
23 cm) pre-equilibrated with TEDP/20 mM 
NaCl/l% sodium cholate. The column was wash- 
ed with 500 ml of the same buffer and elution was 
conducted with 1000 ml of a linear NaCl gradient 
(20-250 mM) in the same buffer and then 500 ml 
of TEDP/SOO mM NaCl/l% sodium cholate 
(fig. 1). Fractions 62-74, containing high GTPyS- 
binding activities, were pooled and concentrated to 
20 ml. The concentrate was fractionated on an 
Ultrogel AcA-44 (LKB) (2.8 x 100 cm) column in 
TEDP/lOO mM NaCl/l% sodium cholate. Frac- 
tions containing GTPyS-binding activity eluted 
from Ultrogel AcA-44 were diluted with 4 vols of 
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Fig. 1. DEAE-Sephacel column chromatography. The activities of [35S]GTPyS-binding and [“P]ADP-ribosylation of each fraction of 
the cholate extract from human platelet membrane separated by DEAE-Sephacel column chromatography were assayed as described 
in [25]. 
91 
Volume 238, number 1 FEES LETTERS September 1988 
TEDP/300 mM NaCl and then applied to a 
phenyl-Sepharose (Pharmacia) (1.6 x 25 cm) col- 
umn pre-equilibrated with TEDP/250 mM 
NaC1/0.25% sodium cholate. After washing with 1 
bed vol. of the same buffer, elution was conducted 
with 300 ml of a linear gradient of 500 mM 
NaC1/0.25% sodium cholate to 25 mM 
NaCl/l.S% sodium cholate in TEDP. The peak 
fraction of GTPyS-binding activity was collected 
and concentrated. The concentrate was diluted 
with 4 vols of TEDP and applied to a Mono Q 
HR5/5 (Pharmacia) column pre-equilibrated 
with TEDP/20 mM NaC1/0.7% 3-[(3-cholami- 
dopropyl)dimethylammonio] - 1 - propanesulfonate 
(Chaps) and elution was conducted (flow rate, 
0.5 ml/min) by using a Pharmacia FPLC system 
with the following gradients of NaCl: 20 mM for 
10 min; 20-300 mM for 40 min; 300-1000 mM 
for 5 min and 1000 mM for 5 min. After the Mono 
Q HR5/5 column chromatography step, pooled 
fractions containing high GTPyS-binding activities 
were diluted with 4 vols of 20 mM Tris-HCl (pH 
8.0)/0.1 mM EDTA/l mM DTT/lOO mM NaCl/ 
0.7% Chaps and applied to a hydroxyapatite 
HCA-100s column (1 x 10 cm) pre-equilibrated 
with the same buffer. The column was washed and 
elution was conducted (flow rate, 0.5 ml/min) by 
using a Pharmacia FPLC system with the follow- 
ing gradients of potassium phosphate (pH 7.5): 
0 mM for 10 min; O-50 mM for 50 min; 50-200 
mM for 3 min; 200 mM for 10 min. This chroma- 
tography resulted in the separation of two protein 
peaks (peak I, fractions 26 and 27; and peak II, 
fractions 28-30) both exhibiting GTPyS-binding 
activity (fig.2). 
As shown in fig.3, both peaks I and II were vir- 
tually homogeneous on SDS-PAGE. The 
molecular mass of peak I was slightly higher than 
that of peak II, but both were approximately 
22 kDa. This value was somewhat lower than the 
estimated molecular mass for v-Ki-ras p21 syn- 
thesized in E. cofi (23 kDa) by SDS-PAGE [25]. 
These two G-proteins were not ADP-ribosylated 
by islet-activating protein (IAP) (not shown). 
Their specific GTPyS-binding activities were 
41.6 nmol/mg protein for both peak I and peak II. 
These proteins bound [35S]GTPyS in a dose- 
dependent manner and Scatchard plot analysis 
showed that 1 mol each of both peaks I and II 
bound maximally 0.89 f 0.3 mol (mean + SE) of 
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Fig.2. Hydroxyapatite (HCA-100s) column chromatography. 
The peak fraction with GTP-binding activity obtained from 
Mono Q HR5/5 column was applied to HCA-100s column and 
the elution was conducted with gradients of potassium 
phosphate (KPi, pH 7.5). OS-ml fractions were collected. 
Further details are in the text. Aliquots (5 ~1) of each fraction 
were assayed for GTP-binding activity. 
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Fig.3. SDS-polyacrylamide gel electrophoresis of the G-proteins 
(peak I and peak II) with molecular mass values of 22 kDa from 
human platelet membranes and rus ~21. Samples (750 ng 
protein) were subjected to gradient (8-16%) SDS- 
polyacrylamide gel electrophoresis. The gel was then stained 
with Coomassie blue (A) or silver (B). Lanes: 1, peak I; 2, peak 
II; 3, rus ~21. The markers (Pharmacia) were phosphorylase b
(94 kDa), bovine serum albumin (67 kDa), ovalbumin 
(43 kDa), carbonic anhydrase (30 kDa), soybean trypsin 
inhibitor (20.1 kDa) and cY-lactalbumin (14.4 kDa). 
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GTPyS with a Kd of 46 * 5 nM (mean + SE) 
(fig.4). The Kd value for peaks I and II is almost 
the same as that determined for a low-molecular- 
mass G-protein, termed 24K G, from bovine brain 
[21] and is 2-4-fold higher than those for Gs, Gi, 
Gt, Go and ras p21 [2,3,6,16,17,26]. As shown in 
fig.5, [35S]GTPyS-binding activity of peak II was 
inhibited by GTP and GDP, but not significantly 
by ATP and AppNHp. The concentrations of GTP 
and GDP required for 50% inhibition were 0.8 and 
1.6 ,uM, respectively. Although data are not 
shown, the binding activity of peak I was similarly 
inhibited by GTP and GDP, but not by ATP and 
AppNHp; 50% inhibition was attained with 
0.56 ,uM GTP and 2.5 ,uM GDP. Finally, it was 
found that a monoclonal antibody raised against v- 
Ki-ras ~21, which recognized not only the antigen 
but also v-Ha-ras p21 and v-N-ras ~21, did not 
cross-react with both peaks I and II (not shown), 
indicating that the latter proteins were distinct 
from rus p21 proteins. 
From these results it can be concluded that 
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Fig.4. Dose-dependence of [?S]GTPyS-binding of the G- 
proteins (peak I and peak II). Peak I or peak II (approx. 62 ng 
protein) was incubated with various concentrations of 
[“S]GTPyS for 2 h at 30°C for measurement of its binding 
activity. The inset shows the Scatchard plots. The results shown 
are representatives of three independent experiments. 
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Fig.5. Effects of various nucleotides on the [“SJGTPyS- 
binding of the major G protein (peak II). Peak II (approx. 
62 ng protein) was incubated with 400 nM [‘sS]GTPyS in the 
presence of various concentrations of the indicated unlabeled 
nucleotides for 2 h at 30°C. The radioactivity of [35S]GTPyS 
bound to the protein in the absence of other nucleotides was 
about IOOOOcpm. (0) GTP, (A) GDP, (0) ATP, (A) 
AppNHp. The results shown arc representatives of three 
independent experiments. 
human platelet membranes contain at least two G- 
proteins of about 22 kDa in addition to the 
heterotrimeric G-proteins whose a-subunits have 
values of about 40 kDa. Since the GTPyS-binding 
capacity is practically the same between these two 
low-molecular-mass G-proteins, the possibility 
cannot be ruled out that peak II has been produced 
from peak I by limited proteolysis. This possibility 
as well as their functions remain to be explored. 
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